Top Ranked Momentum Stocks To Buy For December 30th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:

HealthEquity, Inc. (HQY): This company that provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25% over the last 60 days.

HealthEquity’s shares gained 20.3% over the last one month above the S&P 500’s increase 4.1%. The company possesses a Momentum Score of B.

Sony Corporation (SNE): This company that designs, develops, produces, and sells electronic equipment, instruments, and devices for the consumer, professional, and industrial markets has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.7% over the last 60 days.

Sony’s shares gained 7.1% over the last one month. The company possesses a Momentum Score of B.

Bristol-Myers Squibb Company (NYSE:BMY) (BMY): This company that discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.2% over the last 60 days.

Bristol-Myers Squibb’s shares gained 11.7% over the last one month. The company possesses a Momentum Score of A.

Adaptive Biotechnologies Corporation (ADPT): This company that develops an immune medicine platform for the diagnosis and treatment of various diseases has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 55.3% over the last 60 days.

Adaptive Biotechnologies’ shares gained 6.4% over the last one month. The company possesses a Momentum Score of B.

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>